Robert M. Strieter, M.D.

Robert M. Strieter, MD

Strieter Consulting
Verified email at virginia.edu
Cited by 102734
Early drug development Immunology Inflammation Fibrosis Angiogenesis
Heinz-Josef Lenz

Heinz-Josef Lenz

University of Southern Califfornia
Verified email at usc.edu
Cited by 85049
GI Oncology Molecular Characterization Early Drug Development colon cancer oncology
David M Hyman

David M Hyman

Loxo Oncology, Eli Lilly
Verified email at loxooncology.com
Cited by 41193
Oncology Precision Medicine Cancer Genomics Developmental Therapeutics Early Drug Development
Alexia Iasonos

Alexia Iasonos

Memorial Sloan Kettering Cancer Center
Verified email at mskcc.org
Cited by 14635
biostatistics clinical trials early drug development
Swaminathan Padmanabhan Iyer

Swaminathan Padmanabhan Iyer

Professor of Medicine, University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Cited by 11941
Lymphoma Myeloma Early Drug Development
Glenn J. Hanna, M.D.

Glenn J. Hanna, MD

Associate Professor of Medicine, Harvard Medical School
Verified email at dfci.harvard.edu
Cited by 5071
Head and Neck Oncology Early Drug Development
Raymond P Perez

Raymond P Perez

Verified email at kumc.edu
Cited by 4707
Cancer early drug development phase I
Bashkim Kadriu

Bashkim Kadriu

Executive Director, Translational and Experimental Medicine, Neuroscience at Jazz …
Verified email at jazzpharma.com
Cited by 3188
Mood Disorders Translational Medicine Experimental Therapeutics Early Drug Development and
Paolo Tarantino

Paolo Tarantino

Dana-Farber Cancer Institute, Harvard Medical School
Verified email at dfci.harvard.edu
Cited by 3052
Breast Cancer Early Drug Development HER2 Antibody-Drug Conjugates Immunotherapy
Maarten Huisman

Maarten Huisman

UCB
Verified email at ucb.com
Cited by 2521
Early Drug Development
1 - 10